GSK plc (GSK) Stock Price & Analysis
GSK plc (GSK) closed at USD 51.21 on Thursday, October 22, 2026, up 2.38% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 50.02; the Oct 22, 2026 session ranged USD 49.97–51.44 on volume of 4,283,264 shares. Market capitalization is $102.60B, with a 52-week range of USD 42.85–61.7 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:24 UTC.
Also available as compact Markdown for AI agents: nexqual.com/GSK.md
Key facts (GSK)
- 6 of 80 tracked superinvestors hold GSK (13F, Q2 2026): 0 new, 1 added, 4 reduced, 1 unchanged.
- Analysts: Hold (mean 2.56 on a 1–5 scale) (9 analysts), mean target USD 60.51 (range 49–70).
- Total return with dividends: 1Y +16.4% vs S&P 500 +14.9%; 5Y +57.6% vs S&P 500 +80.3%.
- Next earnings: 2026-10-28, EPS estimate USD 1.33, revenue estimate $8.81B.
Superinvestors (SEC 13F-HR, Q2 2026) (GSK)
6 of 80 tracked investors hold GSK. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Hillman Capital | Hillman Capital Management | 3.51% | $4.8M | Reduced -5.2% |
| Kahn Brothers | Kahn Brothers Group | 1.58% | $8.9M | Unchanged |
| Dodge & Cox Funds | Dodge & Cox | 1.32% | $2.53B | Reduced -17.8% |
| Tweedy Browne | 0.32% | $4.3M | Reduced -0.3% | |
| Richard Pzena | Pzena Investment Management | <0.01% | $1.3M | Added +30.2% |
| Sarah Ketterer | Causeway Capital Management | <0.01% | $375K | Reduced -35.5% |
Analysts (GSK)
Consensus Hold (mean 2.56 on a 1–5 scale), 9 analysts; mean target USD 60.51 (low 49, high 70).
Total return (dividends reinvested) (GSK)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +16.4% | +57.6% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +16.5% | +9.5% |
| Volatility (annualized) | 26.3% | 23.6% |
| Max drawdown | -22.4% (Feb 2026→Oct 2026) | -35.8% (Apr 2022→Sep 2022) |
GSK analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $1.33 | $1.41 | -6.1% | $8.81B | 2 |
| Next quarter (ends Dec 2026) | $0.77 | $0.81 | -4.1% | $8.96B | 2 |
| Current fiscal year (ends Dec 2026) | $4.72 | $4.79 | -1.4% | $33.90B | 5 |
| Next fiscal year (ends Dec 2027) | $4.92 | $5.13 | -4.0% | $35.51B | 5 |
GSK options: expected move
Options price a move of about ±5.6% (±$2.85) by Oct 30, 2026, which includes earnings on Oct 28, 2026.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Oct 30, 2026 | 7 | 46.9% | ±5.6% |
| Nov 6, 2026 | 14 | 35.2% | ±5.7% |
| Nov 13, 2026 | 21 | 31.9% | ±6.6% |
| Nov 20, 2026 | 28 | 29.7% | ±6.8% |
| Nov 27, 2026 | 35 | 28.5% | ±7.2% |
| Dec 18, 2026 | 56 | 27.9% | ±8.8% |
| Jan 15, 2027 | 84 | 25.9% | ±10.0% |
| Feb 19, 2027 | 119 | 26.9% | ±12.5% |
30-day implied volatility 29.6% vs 25.6% realized over the last 30 trading days. Put/call ratio (volume) 0.21. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:24 UTC)
| Price | USD 51.21 |
|---|---|
| Change | ▲ 2.38% (up) |
| Previous Close | USD 50.02 |
| Open | USD 50.29 |
| Day Range | USD 49.97 – 51.44 |
| 52-Week Range | USD 42.85 – 61.7 |
| Volume | 4,283,264 shares |
| Market Cap | $102.60B |
| Exchange | NYQ |
Technical Analysis (GSK)
Nexqual's technical model rates GSK "BUY" based on 5 bullish and 1 bearish signals across 127 daily candles, as of October 23, 2026 at 09:24 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 63.56 (neutral) |
| vs SMA50 | Above (USD 49.56) |
| MACD | 0.18 (positive) |
Analyst Ratings (GSK)
Wall Street analysts rate GSK "Hold" based on 9 analysts, with a mean price target of USD 60.51 (range USD 49–70), per Nexqual as of October 23, 2026 at 09:24 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 60.51 |
| High Target | USD 70 |
| Low Target | USD 49 |
| Buy / Hold / Sell | 4 / 4 / 1 |
Earnings (GSK)
| Next Earnings Date | 2026-10-28 |
|---|---|
| EPS Estimate | USD 1.33 |
| Revenue Estimate | $8.81B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 1.34 vs est 1.25 ▲ beat |
| 2026-03-31 | USD 1.26 vs est 1.16 ▲ beat |
| 2025-12-31 | USD 0.7 vs est 0.62 ▲ beat |
| 2025-09-30 | USD 1.46 vs est 1.26 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:24 UTC.
Financials & Fundamentals (GSK)
| Total Revenue | $33.20B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +5.30% |
| Gross Margin | +73.49% |
| Operating Margin | +30.94% |
| Profit Margin | +14.52% |
| ROE | +33.38% |
| Debt / Equity | 1.06 |
| Current Ratio | 0.82 |
| Total Cash | $3.11B |
| Total Debt | $18.29B |
Source: Nexqual, October 23, 2026 at 09:24 UTC.
Financial Health Score (GSK)
Nexqual rates GSK plc's overall financial health "Solid" across five dimensions, as of October 23, 2026 at 09:24 UTC.
| Growth | Mixed — Revenue +4.1% YoY (annual), slow |
|---|---|
| Profitability | Strong — Gross margin 73%, operating 31% (last 12 months) |
| Balance Sheet | Weak — GBP 3.11B cash vs GBP 18.3B debt |
| Cash Flow | Solid — Operating cash flow GBP 8.33B (TTM) |
| Efficiency | Strong — ROE 33%, ROA 10.0% |
Ownership (GSK)
| Insider Ownership | +0.06% |
|---|---|
| Institutional Ownership | +17.47% |
| Shares Outstanding | 2.00B |
| Float | 1.94B |
| Short % of Float | +0.74% |
Source: Nexqual, October 23, 2026 at 09:24 UTC.
Leadership (GSK)
GSK plc is led by Luke Victor Miels, CEO & Director, per Nexqual as of October 23, 2026 at 09:24 UTC.
| CEO & Director | Luke Victor Miels |
|---|---|
| CFO & Executive Director | Julie Belita Brown A.C.A. |
| Chief Scientific Officer and Head of R & D | Tony Wood |
| President of Corporate Development | David Simon Redfern BSc (Hons), CA |
| President of Global Affairs | Philip C. Thomson |
Major Backers & Investors (GSK)
Notable institutional backers of GSK plc include FMR, LLC, Dodge & Cox Inc., Fisher Asset Management, LLC, according to Nexqual as of October 23, 2026 at 09:24 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 3.21% |
| Dodge & Cox Inc. | 2.38% |
| Fisher Asset Management, LLC | 1.77% |
| Primecap Management Company | 1.24% |
| Fidelity | 1% |
| Wellington Management | 0.56% |
| JTC Employer Solutions Trustee Ltd. | 0.42% |
| Morgan Stanley | 0.38% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.56% |
Source: Nexqual, October 23, 2026 at 09:24 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SNY | Sanofi | USD 41.96 | ▲ 2.42% |
| BMY | Bristol-Myers Squibb Company | USD 63 | ▲ 3.08% |
| PFE | Pfizer, Inc. | USD 30.42 | ▲ 1.91% |
| NVO | Novo Nordisk A/S | USD 39.43 | ▲ 0.95% |
| GILD | Gilead Sciences, Inc. | USD 157.19 | ▲ 2.36% |
| AMGN | Amgen Inc. | USD 447.28 | ▲ 2.04% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:24 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt